Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

We describe a case of a 46-year-old woman diagnosed with localized PTC 20 years ago, having already undergone several treatments with iodine-131 and then treatment with lenvatinib for metastatic disease, to which she developed intolerance. In 2020, in addition to pleural, thoracic, and abdominal lym...

Full description

Bibliographic Details
Main Authors:	Joana S. Reis, Inês Costa, Mariana Costa, Ana Carmo Valente, Marta Baptista Freitas, Catarina Lopes Almeida, Marina Gonçalves, Carina Teixeira, Maria Ribeiro, Cláudia Caeiro, Catarina Fernandes, Miguel Barbosa
Format:	Article
Language:	English
Published:	Karger Publishers 2022-11-01
Series:	Case Reports in Oncology
Subjects:	precision oncology braf mutation metastatic thyroid cancer braf inhibitors lenvatinib intolerance
Online Access:	https://www.karger.com/Article/FullText/526533

Similar Items

BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT
by: Ivana Inić, et al.
Published: (2014-09-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
by: Francesca Consoli, et al.
Published: (2020-07-01)

Clinical significance of <it>BRAF </it>mutations in metastatic melanoma
by: Polsky David, et al.
Published: (2004-12-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
by: Dahlia Fedele, et al.
Published: (2024-01-01)

Clinical associations and genetic interactions of oncogenic BRAF alleles
by: Sebastian A. Wagner
Published: (2022-10-01)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01)

The possibilities of therapy of patients with metastatic colorectal cancer with <i>BRAF</i> V600E mutation. Clinical cases
by: Elizaveta M. Polyanskaya, et al.
Published: (2023-05-01)

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
by: Morgane Broudic-Guibert, et al.
Published: (2019-07-01)

PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION
by: M. Yu. Fedyanin, et al.
Published: (2015-02-01)

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
by: Laure Moisset, et al.
Published: (2019-06-01)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
by: Silvia Mezi, et al.
Published: (2023-09-01)

Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Maximilian Haist, et al.
Published: (2022-04-01)

Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma
by: Maxime Brunet, et al.
Published: (2019-11-01)

NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma
by: Valentina Audrito, et al.
Published: (2020-12-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
by: Ernesto Rossi, et al.
Published: (2023-01-01)

Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
by: Baptiste Louveau, et al.
Published: (2019-08-01)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01)

BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey
by: Nuray CAN, et al.
Published: (2018-05-01)

Factors influencing the prognosis in Braf wild-type metastatic malignant melanoma and the role of novel inflammation indices
by: Senar Ebinç, et al.
Published: (2023-09-01)

The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
by: Angela Djanani, et al.
Published: (2020-11-01)

The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis
by: Liu-Fang Ye, et al.
Published: (2021-08-01)

Modern options in personalized therapy of metastatic cutaneous melanoma
by: S A Protsenko, et al.
Published: (2014-09-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
by: Alessandro Nepote, et al.
Published: (2022-02-01)

Comparison of Two Rapid Assays for the Detection of <i>BRAF</i> V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes
by: Elodie Long-Mira, et al.
Published: (2022-03-01)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
by: Vasu Munjapara, et al.
Published: (2022-10-01)

Combined analysis of BRAF-gene mutation and galectin-3 expression in preoperative diagnostics of thyroid cancer
Published: (2011-06-01)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
by: Paola Savoia, et al.
Published: (2020-12-01)

Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta‐analysis
by: Lauren C. Bylsma, et al.
Published: (2020-02-01)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in <i>BRAF</i>V600 Melanoma: Current Status and Future Perspectives
by: Michèle Welti, et al.
Published: (2022-11-01)

Braf protein mutation and its significancy within patients with melanoma
by: Julia Kuchnicka, et al.
Published: (2022-08-01)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
by: Junjia Liu, et al.
Published: (2023-09-01)

Določanje mutacije V600E v genu BRAF
by: Petra Škerl, et al.
Published: (2010-12-01)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
by: Gerardo Rosati, et al.
Published: (2021-03-01)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
by: Matthias Lang, et al.
Published: (2023-03-01)

BRAF mutation and its inhibitors in sarcoma treatment
by: Haotian Liu, et al.
Published: (2020-07-01)

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
by: JIANG Jianyun, YING Hongmei
Published: (2022-05-01)

Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma Patients
by: Martin Salzmann, et al.
Published: (2020-10-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
by: Simeng Zhang, et al.
Published: (2023-01-01)